Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 138,674,416
  • Shares Outstanding, K 5,685,708
  • Annual Sales, $ 63,627 M
  • Annual Income, $ 8,031 M
  • EBIT $ 18,723 M
  • EBITDA $ 25,736 M
  • 60-Month Beta 0.54
  • Price/Sales 2.18
  • Price/Cash Flow 5.60
  • Price/Book 1.49

Options Overview Details

View History
  • Implied Volatility 25.68% ( +1.99%)
  • Historical Volatility 28.66%
  • IV Percentile 50%
  • IV Rank 21.91%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Put/Call Vol Ratio 0.19
  • Today's Volume 282,747
  • Volume Avg (30-Day) 226,365
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 3,725,845
  • Open Int (30-Day) 3,598,021

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.66
  • Number of Estimates 4
  • High Estimate 0.77
  • Low Estimate 0.55
  • Prior Year 0.63
  • Growth Rate Est. (year over year) +4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.91 +5.79%
on 11/10/25
25.30 -0.02%
on 11/11/25
+0.51 (+2.07%)
since 10/10/25
3-Month
23.58 +7.27%
on 09/25/25
27.69 -8.65%
on 10/03/25
+0.71 (+2.91%)
since 08/11/25
52-Week
20.92 +20.94%
on 04/09/25
27.69 -8.65%
on 10/03/25
-0.95 (-3.60%)
since 11/11/24

Most Recent Stories

More News
The Top 5 Analyst Questions From Pfizer’s Q3 Earnings Call

The Top 5 Analyst Questions From Pfizer’s Q3 Earnings Call

PFE : 25.34 (+3.90%)
3 Cash-Producing Stocks We Think Twice About

3 Cash-Producing Stocks We Think Twice About

FDS : 271.49 (+2.41%)
K : 83.31 (-0.01%)
PFE : 25.34 (+3.90%)
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

MTSR : 70.65 (-0.31%)
PFE : 25.34 (+3.90%)
Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

AZN.LN : 13,466.000 (+2.59%)
PFE : 25.34 (+3.90%)
3 Value Stocks That Fall Short

3 Value Stocks That Fall Short

SEE : 37.30 (+1.19%)
SIRI : 21.73 (+0.09%)
PFE : 25.34 (+3.90%)
Pfizer Responds to Delaware Chancery Court Ruling

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc....

PFE : 25.34 (+3.90%)
Wall Street gains ground amid steady flow of earnings reports, upbeat economic updates

Stocks gained ground on Wall Street following several upbeat economic updates and a steady flow of quarterly reports from U.S. companies

GOOGL : 290.38 (+0.10%)
AVGO : 354.20 (-1.17%)
EXPE : 266.41 (-0.61%)
AXON : 566.00 (-3.20%)
IFF : 64.92 (+3.41%)
$IUXX : 25,558.55 (-0.21%)
PFE : 25.34 (+3.90%)
MSFT : 509.10 (+0.61%)
TSLA : 437.16 (-1.81%)
QCOM : 174.03 (+1.43%)
AMD : 240.08 (-1.60%)
$DOWI : 47,912.99 (+1.15%)
PFE Q3 Deep Dive: Pipeline, Cost Controls, and Business Development Shape Outlook

PFE Q3 Deep Dive: Pipeline, Cost Controls, and Business Development Shape Outlook

PFE : 25.34 (+3.90%)
Losses for Big Tech pull Wall Street lower

Stocks fell on Wall Street, pulled down by losses in the same big tech companies that have been the main drivers of the market's rally so far this year

KMB : 103.20 (+0.11%)
NVDA : 193.88 (-2.60%)
MTSR : 70.65 (-0.31%)
$SPX : 6,851.30 (+0.28%)
EXPE : 266.41 (-0.61%)
$IUXX : 25,558.55 (-0.21%)
PFE : 25.34 (+3.90%)
MCD : 305.66 (+2.19%)
MSFT : 509.10 (+0.61%)
IREN : 56.99 (-5.29%)
YUM : 150.50 (+1.51%)
TSLA : 437.16 (-1.81%)
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera

MTSR : 70.65 (-0.31%)
$SPX : 6,851.30 (+0.28%)
$DOWI : 47,912.99 (+1.15%)
$IUXX : 25,558.55 (-0.21%)
PFE : 25.34 (+3.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 25.85
2nd Resistance Point 25.37
1st Resistance Point 24.88
Last Price 25.34
1st Support Level 23.90
2nd Support Level 23.42
3rd Support Level 22.93

See More

52-Week High 27.69
Last Price 25.34
Fibonacci 61.8% 25.10
Fibonacci 50% 24.30
Fibonacci 38.2% 23.50
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar